Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-09-01

Clinical Trial Update: Sorafenib Long Term Extension Program [Phase 3]

View source ↗

Summary

A Phase 3 long-term extension trial update for sorafenib in neoplasms has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sorafenib (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2022-09-01